Cell therapeutic approaches to treat a range of congenital and degenerative neuropathies are under 16 intense investigation. There have been recent significant advancements in the development of cell 17 therapy to treat disorders of the enteric nervous system, enteric neuropathies. These advances 18 include the efficient generation of enteric neural progenitors from pluripotent stem cells and the 19 rescue of a Hirschsprung disease model mouse following their transplantation into the bowel. 20
Introduction 26
The enteric nervous system (ENS) is composed of an extensive network of neurons and glia 27 embedded within the gastrointestinal (GI) tract and it plays a vital role in nutrient and water 28 absorption, hormone secretion and gastrointestinal motility (25) . Most of the ENS is derived from 29 vagal (caudal hindbrain) neural crest cells, which migrate into and then along the bowel during 30 embryonic development (7). This migration occurs over a long migratory route due to the growth of 31 the gut, and consequently occurs over extended periods of gestation; ~5 weeks (or 12.5%) of 32 gestation in humans (68) and 5 days (or 25%) of gestation in mice (40). In addition to vagal neural 33 crest, there are two other minor sources of enteric neurons: Sacral neural crest cells contribute 34 some neurons to the distal bowel (10, 39), although sacral cells cannot compensate for a loss of 35 vagal neural crest cells (8), and Schwann cell precursors, which enter the bowel via extrinsic nerves 36 during late embryonic and postnatal development, and have recently been shown to give rise to 37 some enteric neurons in the small and large intestines (67). The resulting ENS is a complex 38 interconnected network containing approximately 500 million neurons in humans; more than the 39 spinal cord (24, 26) . Gut motility disorders can arise from the loss of subtypes of enteric neurons as 40 occurs in some forms of diabetic gastroparesis, achalasia and Chagas disease (28, 42, 50, 58) , or the 41 congenital absence of the ENS, which occurs in Hirschsprung disease (6, 12, 31, 44, 49, 54) . GI 42 motility disorders caused by enteric neuropathies are some of the most clinically challenging GI 43 conditions to manage (18) (19) (20) 42) and thus there has been considerable interest in the potential of 44 cell therapy to treat such disorders (9, 11, 28) . 45
During development, enteric neural crest cells colonise the gut by migrating through an 46 undifferentiated loose mesenchyme of the gut tube (32). However, for cell therapy, transplanted 47 progenitor cells will have to migrate in a mature, differentiated and layered muscular gut tube. 48
Moreover, key signalling molecules that drive the migration of enteric neural crest cells during 49 development may not be expressed at the same levels in the postnatal gut as they are in the 50 embryonic gut (32). Despite these challenges, many studies have shown migration of progenitors 51 following engraftment in the postnatal gut (15-17, 22, 35, 46, 62) , although manipulation of 52 signalling pathways might be required to enhance engraftment outcomes (48). 53
Cell therapy requires an accessible source of ENS progenitor cells to transplant into the bowel. Three 54 recent studies have demonstrated the generation of enteric neural progenitors from human 55 pluripotent stem cells (PSCs), utilising them for transplantation in small animal models, or for in vitro 56 modelling of Hirschsprung disease (22, 46, 69) . Fattahi et al (2016) and Li et al (2016) showed that 57 enteric neural precursors could be generated from human PSCs, and following transplantation into 58 the colon of adult mice, the precursors migrated and generated enteric neurons. Moreover, 59
transplantation of human PSC-derived enteric neuron precursors into the colon of a mouse model of 60 Hirschsprung disease, mortality was rescued (22). Some of the aforementioned studies also utilised 61 PSC-derived enteric neural progenitors with Hirschsprung-associated gene mutations to model the 62 disease-in-a-dish (22, 66, 69) . These recent, ground-breaking studies demonstrate the potential of 63 pluripotent stem cell technology to treat GI motility disorders. As attempts to develop cell 64 therapeutic approaches to treat enteric neuropathies gain momentum, it is important step back and 65 assess the current standing and future directions of this growing field of regenerative medicine. 66 Recent reviews of the field (9, 11) have provided comprehensive overviews of the GI motility 67 disorders that could be targeted by cell therapy and of studies using animal models of the potential 68 of cell therapy to treat motility disorders. This mini-review discusses recent findings using human 69
PSCs to generate enteric neurons and compares PSC-derived cells to endogenous enteric neural 70 progenitors as a source of enteric neurons for cell therapy. A set of key steps for the treatment of 71
Hirschsprung disease using cell therapy is also proposed. The growing evidence of the potential of stem cell-based therapies for the treatment of gut motility 139 disorders, using either endogenous enteric neural progenitors or pluripotent stem cell-derived 140 precursors as a source of enteric neurons, is cause for great excitement. However, different cell 141 sources have advantages and disadvantages, which are summarized in Table 1 and some of these  142 properties are discussed in more detail below. 143 
PROPERTIES OF STEM CELLS FOR ENS CELL THERAPY

Endogenous ENS progenitors Embryonic stem (ES) cells
Induced pluripotent stem (iPS) cells Autologous origin
Yes (1, 3-5, 15, 16, 33, 35, 36, 43, 52, 55) No (65) Yes (30, 63) Capacity for expansion Limited (43, 47, 48) Infinite (57, 65) Infinite (63)
Demonstrated long-term survival
Yes (~24 months in mouse models)
Not yet (<3 months)
Safety (no tumour formation) Yes (no tumour formation 24 months after transplantation) (16, 35) Yes (no tumour formation 3 months after transplantation) (22) Not yet demonstrated
Neuronal differentiation
Yes; multiple neuronal subtypes (1, 15, 16, 33, 35, 43, 52) Yes; multiple neuronal subtypes (22) Yes; multiple neuronal subtypes (22, 46, 69) 
Directed differentiation of stem cells to generate specific enteric neuron subtypes
Not yet demonstrated
Functional neurons following transplantation into the bowel of rodents
Yes; action potentials, fEPSPs and calcium transients (16, 35, 62) Not yet demonstrated and enteric neuropathies can affect all regions of the GIT. It will therefore be important to 212 demonstrate that graft-derived neurons contribute to the appropriate, region-specific circuitry and 213 restoration of motility patterns. 214
Not yet demonstrated
Integration of transplanted cells
Yes
Key Steps to Cell Therapy for Hirschsprung Disease 215
The key steps likely to be required for the treatment of infants with Hirschsprung disease using cell 216 therapy are shown in Box 1. While these proposed steps are focused on cell therapy for 217
Hirschsprung disease, many will be applicable to treatment of other enteric neuropathies as well. 218
However, additional keys steps, such as the directed differentiation to specific enteric neuron 219 subtypes (discussed above) may also be required for diseases like achalasia. The first step is an 220 important aspect of the Hirschsprung disease cell therapy process, which will be the creation of a 221 temporary stoma to by-pass the obstruction and prevent enterocolitis. The second step is isolation 222 of patient-derived cells. The source of these cells will depend on the stem/progenitor cell to be used 223 for transplantation, with endogenous ENS progenitors isolated from the normo-ganglionated regions 224 of bowel by routine endoscopy (52) growing the PSC-derived enteric progenitors as spheroids, injected 2-4 x 10 6 cells as a single cell 250 suspension. Further, these cells were injected into the caecum, rather than the aganglionic distal 251 colon, in studies using Hirschsprung disease-model mice. The optimal method for delivering the 252 progenitors to patient bowel should be minimally invasive but accurate and repeatable. 253
Finally, time will play an important role, which can be made available to Hirschsprung disease 254 patients following the creation of a temporary enterostomy (proposed in step 1). In addition to 255 allowing time for the expansion of progenitors, it will also take time for the migration, differentiation 256 and maturation of neurons and glia following transplantation of cells. 257
This proposed cell therapeutic approach may ultimately prove to be unrealistic in some patients, 258
particularly those with long-segment Hirschsprung disease. An alternative approach could be to use 259 cell therapy as an adjunct treatment to surgical resection, implanting progenitors to in the distal 260 colon (including any residual transition zone or aganglionic muscular sleeve), to improve post-261 operative outcomes. 262
263
Conclusions 264
Significant advances have been made by numerous research groups in the development of 265 approaches to apply neural stem cell-based therapy to treat gut motility disorders (9). The recent 266 production of pluripotent stem cell-derived enteric neural crest precursors (22, 46, 69) and their 267 successful transplantation into recipient mouse colon (22, 46) , and our demonstration of functional 268 innervation of the colonic muscle of recipient mice in vivo by graft-derived neurons (62), has 269 resulted in increased awareness of the field and a consolidation of efforts to move this research 270 toward the clinic. This should occur only after addressing some of the above outstanding questions 271 in animal models of enteric neuropathies and only in a coordinated effort with expert clinicians and 272 surgeons. 273
